Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sara K. Hansen, Marcelina Párrizas, Maria L. Jensen, Stepanka Pruhova, Jakob Ek, Sylvia F. Boj, Anders Johansen, Miguel A. Maestro, Francisca Rivera, Hans Eiberg, Michal Andel, Jan Lebl, Oluf Pedersen, Jorge Ferrer, Torben Hansen
Published in Volume 110, Issue 6
J Clin Invest. 2002; 110(6):827–833 doi:10.1172/JCI15085
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Expression of HNF-4α transcripts in human tissues. (a) Schematic representation of possible combinations of HNF-4α splice variations (adapted from ref. 27). Numbers indicate exons. Arrows indicate oligonucleotides used for RT-PCR. (b) RT-PCR analysis of HNF-4α exon 1A (transcribed from the P1 promoter) versus exon 1D (transcribed from the P2 promoter) in pancreatic tissues and liver. β-actin is used as internal control for the RT-PCR procedure. Only one band is amplified using primers designed to amplify HNF-4α exon 1A+2, indicating that transcripts originating in either tissue do not contain exon 1B. (c) RT-PCR analysis of HNF-4α 3′ end splice variations in human islets and liver. The 8F+10R primer set amplifies two fragments containing or lacking an extended exon 9 (9+) insertion. According to these results, liver contains predominantly HNF-4α1, -4α2, and -4α3 transcripts, whereas pancreatic cells contain HNF-4α7, -4α8, and -4α9 variants.